The EYE GLAZ · Jun 29, 2026
Potential neuroprotective role of statins in glaucoma prevention and treatment: a literature review of clinical studies
By Chuprov AD, Trubnikov VA, Startseva MI
Background . Glaucoma is one of the leading causes of blindness and visual impairment worldwide. As of January 1, 2022, approximately 1.2 million people with glaucoma were registered in the Russian Federation, including 101 000 individuals with visual disability. The rising prevalence of glaucoma is associated with population aging and a high burden of comorbidity in older adults. This makes the search for new approaches to preventing glaucoma-related blindness and improving glaucoma treatment particularly relevant. Purpose : To investigate the association between statin use and the development or progression of glaucoma. Materials and methods . A systematic literature search was conducted in PubMed, Google Scholar, Web of Science, Scopus, and eLibrary for publications from 2000 to 2025. The search terms were glaucoma, statins, cholesterol, and primary openangle glaucoma. Eligible publications included original studies, meta-analyses, and systematic reviews examining the association between statin use and glaucoma. Overall, 38 publications were included, of which 25 were original studies. Results. Most of the studies reviewed suggest a potential protective effect of statins in glaucoma. Long-term statin use, defi ned as treatment for more than 2–3 years, was associated with a 21–40 % lower risk of developing primary open-angle glaucoma. Several mechanisms have been proposed, including neuroprotection of retinal ganglion cells through improved microcirculation and reduced apoptosis and cytotoxicity; modulation of immune responses; and a potential reduction in intraocular pressure through improved aqueous humor outfl ow. Conclusion. This literature review indicates a complex and heterogeneous association between statin use and open-angle glaucoma development. Although most findings suggest a potential benefit, the evidence remains inconsistent. Large randomized clinical trials are needed to confirm the neuroprotective effects of statins in glaucoma. The available data may inform the development of new statin-based therapeutic strategies for glaucoma management.
doi.org/10.33791/2222-4408-2026-2-155-162Open accessInterventions